Scarica l'app Stockscreener
52.32
2.84%
-1.53
Pre-mercato:
53.20
0.88
+1.68%
Precedente Chiudi:
$53.85
Aprire:
$54.16
Volume 24 ore:
2.81M
Relative Volume:
1.35
Capitalizzazione di mercato:
$10.05B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
19.45
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
-5.61%
1M Prestazione:
-4.00%
6M Prestazione:
-7.10%
1 anno Prestazione:
-25.10%
Intervallo 1D:
$51.78
$54.25
Intervallo di 1 settimana:
$51.78
$56.26
Portata 52W:
$51.78
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.32 | 10.34B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Ascendis Pharma Develops Sustained-Release Therapy to Compete with BioMarin’s Voxzogo for Achondroplasia Treatment - geneonline.com
BioMarin Pharmaceutical Inc. stock outlook for YEARJuly 2025 Fed Impact & AI Powered Market Entry Strategies - newser.com
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Understanding BioMarin Pharmaceutical Inc.’s price movementProduct Launch & Real-Time Chart Pattern Alerts - newser.com
What MACD signals say about BioMarin Pharmaceutical Inc.Profit Target & Fast Exit/Entry Strategy Plans - newser.com
Can BioMarin Pharmaceutical Inc. stock reach $100 price targetQuarterly Market Summary & Weekly Chart Analysis and Trade Guides - newser.com
Board of the Pension Protection Fund Invests $445,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 12-Month LowTime to Sell? - MarketBeat
Leerink Partnrs Has Negative Outlook of BMRN Q1 Earnings - MarketBeat
Callan Family Office LLC Purchases 47,264 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - TradingView
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD By Investing.com - Investing.com South Africa
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD - Investing.com India
Relative strength of BioMarin Pharmaceutical Inc. in sector analysisQuarterly Investment Review & Community Trade Idea Sharing - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $119.00 - MarketBeat
Real time social sentiment graph for BioMarin Pharmaceutical Inc.2025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
BioMarin Pharmaceutical's (BMRN) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
What data driven models say about BioMarin Pharmaceutical Inc.’s futureMarket Trend Report & Fast Exit Strategy with Risk Control - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? - MSN
Biomarin Pharmaceutical expects Q3 will include acquired IPR&D charges of about $221 million - MarketScreener
BioMarin projects $221 million IPR&D charge from Inozyme acquisition - Investing.com
AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.
14 Biotech Stocks with High Potential - Insider Monkey
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - sharewise.com
Real time alert setup for BioMarin Pharmaceutical Inc. performanceIPO Watch & Reliable Intraday Trade Plans - newser.com
How BioMarin Pharmaceutical Inc. stock performs in stagflationM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Should Positive Phase 3 PALYNZIQ Results Prompt Action From BioMarin (BMRN) Investors? - Sahm
Robeco Institutional Asset Management B.V. Increases Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc.’s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials - MSN
Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story? - Yahoo Finance
J. Safra Sarasin Holding AG Boosts Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. stock a safe buy before earningsMarket Weekly Review & Momentum Based Trading Ideas - newser.com
BioMarin Pharmaceutical (BMRN): Evaluating Valuation as PALYNZIQ Clinical Success Contrasts With 52-Week Share Price Low - Sahm
How institutional ownership impacts BioMarin Pharmaceutical Inc. stockPortfolio Return Report & Free Accurate Trade Setup Notifications - newser.com
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors - Insider Monkey
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline - Yahoo Finance
New Wave Wealth Advisors LLC Raises Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low - Yahoo Finance
The Best Biotech Stocks to Buy - Morningstar
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
Take Care Before Diving Into The Deep End On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
PGGM Investments Has $28.47 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
7 Most Promising Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks - Seeking Alpha
Tealwood Asset Management Inc. Increases Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):